巨细胞动脉炎——新的治疗靶点即将出现。
Giant cell arteritis - New treatment targets at the horizon.
作者信息
Thiel Jens
机构信息
Division of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Freiburg, Freiburg/Breisgau, Germany.
出版信息
Semin Arthritis Rheum. 2025 Jun;72S:152686. doi: 10.1016/j.semarthrit.2025.152686. Epub 2025 Feb 27.
Increasing insights into the pathogenesis of giant cell arteritis (GCA) identified a large number of new treatment targets. Very recently clonal hematopoesis, immune ageing processes associated with inflammation and dysregulated immune checkpoints have been linked to the pathogenesis of GCA. Based on pathopyhsiological insights new treatment options such as Janus kinase inhibitors or IL-17A blocking antibodies are currently tested in GCA.
对巨细胞动脉炎（GCA）发病机制的深入了解揭示了大量新的治疗靶点。最近，克隆性造血、与炎症相关的免疫衰老过程以及失调的免疫检查点已与GCA的发病机制相关联。基于病理生理学见解，目前正在GCA中测试诸如Janus激酶抑制剂或IL-17A阻断抗体等新的治疗选择。
Zotero 插件